Glioblastoma is an aggressive malignancy marked by rapid progression and a dismal median survival time of only eight months post-diagnosis. Traditional treatment modalities such as chemotherapy and surgery often yield limited efficacy. Immunotherapies, heralded for their revolutionary impact in multiple cancer types, have thus far failed to achieve significant success with glioblastoma due largely to the brain’s unique immune environment. The blood-brain barrier restricts immune cell infiltration, and the tumor microenvironment actively suppresses immune activity, leaving the cancer shielded from many therapeutic interventions.

TTFields therapy emerges as a novel biophysical approach, employing low-intensity, alternating electric fields to disrupt the mitotic processes of cancer cells. Delivered via strategically placed electrode arrays over the scalp, TTFields interfere with polarized intracellular components essential for cell division. This continual disruption impairs the ability of glioblastoma cells to proliferate, halting tumor growth. Moreover, patients typically wear the device for about 18 hours daily, maintaining consistent therapeutic exposure.

Beyond mere growth inhibition, the intriguing immunomodulatory effect of TTFields has captured scientific interest. The therapy appears to elevate the infiltration and persistence of tumor-fighting T cells—immune cells fundamental to cancer eradication—within and surrounding glioblastoma tissues. By fostering a more immunologically active tumor microenvironment, TTFields prime the battlefield for immunotherapy agents to exert more potent effects.

The immunotherapy employed in this study is pembrolizumab, a checkpoint inhibitor known for reinvigorating exhausted T cells by blocking the PD-1 immune checkpoint pathway. While pembrolizumab has had limited success as a standalone treatment for glioblastoma, its combination with TTFields aims to overcome the tumor’s immune evasion mechanisms by first recruiting and sustaining effector T cells locally.

Experimental evidence presented in the phase 2 clinical trial 2-THE-TOP demonstrated that administering TTFields alongside standard chemotherapy (temozolomide) and pembrolizumab led to a remarkable 70% increase in overall survival compared with historical controls treated with TTFields plus chemotherapy alone. Particularly notable was the robust benefit observed in patients with large, unresected tumors—a subgroup typically associated with poor outcomes.

In these patients, the augmented immune response likely stems from the presence of more tumor antigens, which, when combined with the disruptive electric fields, effectively ignite localized immune activation. The result is a more vigorous and sustained anti-tumor immune attack potentiated by pembrolizumab’s checkpoint blockade.

Dr. David Tran, chief of neuro-oncology at Keck Medicine and lead author, elucidates this synergy as a strategic “team sport” wherein TTFields destabilize tumor defenses, providing an opening for immunotherapy to successfully mobilize the immune system’s offensive arsenal. This dual-pronged assault overcomes the immunosuppressive barriers of glioblastoma, offering a therapeutic breakthrough.

The study enrolled 31 patients newly diagnosed with glioblastoma who had completed chemoradiation. Twenty-six participants received the tripartite treatment regimen, with six to twelve months of chemotherapy, continuous TTFields application up to 24 months, and pembrolizumab infusions every three weeks beginning after the initial chemotherapy cycles. Outcomes revealed extended survival times and elevated T cell activity, underscoring the clinical and immunological potential of the combined treatment.

Importantly, the research also opens questions about the role of surgical tumor resection in the context of these therapies. Patients unable to undergo tumor removal appeared to benefit even more significantly, suggesting that the presence of the tumor mass serves as a substrate that TTFields and immunotherapy can exploit to launch a heightened immune response. Future investigations aim to clarify this relationship and optimize treatment protocols accordingly.

Keck Medicine is now advancing this line of inquiry in a multicenter phase 3 clinical trial enrolling over 700 glioblastoma patients worldwide. This pivotal study, led by Dr. Tran as the steering committee chair, will rigorously assess the efficacy and safety of the combined TTFields, pembrolizumab, and chemotherapy approach across diverse patient populations and tumor resection statuses.

The promise of TTFields lies not only in its direct cytostatic effects but also its capacity to reshape the neuro-oncological immunological landscape—a key barrier that has thwarted many previous immunotherapeutic attempts. Its integration into comprehensive treatment regimens may ultimately redefine standards of care for glioblastoma, a cancer that for decades has defied effective longue durée management.

With ongoing research and clinical validation, TTFields combined with immunotherapy represents a beacon of hope, signaling a transformative shift toward harnessing physical and immune-mediated strategies in unison to combat one of the most formidable brain tumors known to medicine.

Subject of Research: People

Article Title: Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: A phase 2 study

News Publication Date: 3-Jun-2025

Web References:

• Clinical Trial NCT03405792: https://clinicaltrials.gov/study/NCT03405792
• Clinical Trial NCT06556563: https://clinicaltrials.gov/study/NCT06556563

References:
Tran DD, Chen D, Le S, et al. Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: A phase 2 study. Med. 2025; doi:10.1016/j.medj.2025.100708.

Image Credits: Image used with permission from Novocure GmbH

Keywords: Glioblastomas, Brain cancer, Cancer, Immunotherapy, Health and medicine

Glioblastoma stem cells represent a formidable challenge due to their ability to survive current therapeutic regimens and subsequently regenerate tumors, leading to inevitable relapse. Unlike the bulk tumor cells that may respond to surgery and chemoradiation, these stem-like cells exhibit remarkable adaptability and resistance. Dr. Samy Lamouille, an assistant professor at the Fralin Biomedical Research Institute and the lead author of this study, emphasizes the significance of targeting this cancer cell subpopulation, highlighting that their dormancy and later reactivation underline their critical role in tumor recurrence. The novel JM2 peptide therapy is designed specifically with this problem in mind.

The key to this innovative approach lies in the molecular interaction between connexin 43, a protein traditionally known for its role in forming gap junctions allowing cell-to-cell communication, and the cytoskeletal microtubules within glioblastoma stem cells. Using super-resolution microscopy, Dr. Lamouille and his collaborators unraveled an intricate association where connexin 43 decorates microtubules along their entire length within these malignant stem-like cells. This discovery reveals a heretofore unknown intracellular function of connexin 43 that supports the survival and tumorigenic capacity of glioblastoma stem cells.

This pivotal insight informed the design of JM2, a peptide derived from the microtubule-interacting domain of connexin 43. JM2 acts by disrupting this critical protein-microtubule interaction selectively within glioblastoma stem-like cells. Remarkably, while it interferes with this specific pathological mechanism, JM2 spares the other vital physiological roles of connexin 43, minimizing potential off-target effects. This selectivity underscores JM2’s therapeutic potential by efficiently targeting cancerous cells while leaving healthy brain tissue unharmed.

JM2 was initially developed by Dr. Rob Gourdie and his team at the Medical University of South Carolina, in collaboration with the Virginia Tech researchers. Preliminary experiments led by Dr. Lamouille’s lab demonstrated JM2’s impressive ability to induce cell death specifically in glioblastoma stem-like cells in vitro. The experimental data showed that JM2 significantly shrinks three-dimensional gliospheres—clusters of stem-like tumor cells grown in culture—suggesting potent tumoricidal effects intrinsic to the peptide.

Further in vivo studies strengthened these findings by revealing that JM2 substantially suppresses tumor growth in animal models. This effect is particularly important, as it offers tangible evidence that targeting connexin 43-microtubule interactions can impair the maintenance and tumorigenicity of glioblastoma stem cells in a manner that could be translatable to clinical therapy. It also represents a potential paradigm shift in glioblastoma treatment strategies, shifting the focus from bulk tumor eradication to directly targeting the root cause of recurrence.

The research excavates a previously unappreciated role of connexin 43 in cancer biology. Traditionally viewed as a tumor suppressor or facilitator depending on its location and expression levels, connexin 43’s interaction with microtubules in the cytoplasm appears to support the maintenance of glioblastoma stem cells. JM2’s mechanism of action injects fresh momentum into the study of connexin proteins as complex molecules with dualistic roles in cancer progression and treatment resistance.

This work also highlights the synergy between advanced imaging technologies, such as super-resolution microscopy, and molecular biology. The ability to visualize nanoscale protein arrangements within cancer cells provided the experimental window necessary to uncover the connexin 43-microtubule relationship. These technical advances empower researchers to reveal new targets and therapeutic avenues that were previously unreachable, potentially accelerating translational cancer research in the near future.

Moreover, the interdisciplinary collaboration between Virginia Tech’s Fralin Biomedical Research Institute and Carilion Clinic exemplifies the integration of basic science and clinical resources. Access to glioblastoma cells derived from consenting patients treated by Carilion physicians enabled cutting-edge experimental setups that closely mimic human disease conditions. This translational research model fosters innovations aimed at real-world clinical challenges, including the urgent need to tackle glioblastoma’s notorious treatment resistance and recurrence.

While JM2’s promise is robust in preclinical settings, the pathway towards human application will require extensive further research. Future efforts will focus on optimizing delivery mechanisms to guide JM2 precisely to glioblastoma cells, enhancing its therapeutic index. Investigators are exploring biodegradable nanoparticles and viral vector systems as potential carriers that could selectively release JM2 within tumor microenvironments, minimizing systemic exposure and side effects.

Importantly, Lamouille and Gourdie have co-founded Acomhal Research Inc., a start-up licensing the JM2 peptide with the goal of developing new targeted therapies for cancer patients. This commercialization step reflects the translational potential of fundamental discoveries from academic research to clinically viable treatments, aiming to bring hope to patients facing this devastating brain cancer.

In summary, the discovery and development of the JM2 peptide signify a landmark advance in glioblastoma research. By elucidating and targeting the novel role of connexin 43-microtubule interactions in glioblastoma stem cell biology, this work opens an unprecedented therapeutic window. The selective toxicity of JM2 towards resistant cancer stem-like cells while sparing normal brain cells underscores its potential as a groundbreaking peptide-based therapeutic. If successful in clinical translation, JM2 could transform glioblastoma treatment paradigms, improving survival and quality of life for countless patients globally.

Subject of Research: Cells

Article Title: Cytoplasmic connexin43-microtubule interactions promote glioblastoma stem-like cell maintenance and tumorigenicity

News Publication Date: 16-May-2025

Web References: https://doi.org/10.1038/s41419-025-07514-2

Image Credits: Samy Lamouille/Virginia Tech

Keywords: Health and medicine, Medical treatments, Biomedical engineering, Glioblastomas, Cancer

Astrocytes are abundant and highly versatile cells found throughout the central nervous system. Traditionally, they have been regarded primarily as supportive cells for neurons, involved in maintaining blood-brain barrier integrity, regulating neurotransmitter levels, and modulating synaptic activity. However, emerging evidence has highlighted their critical role in immune regulation in the brain. The current study delves into this immune-modulating ability of astrocytes and unveils a specific subset that acts as an accomplice to GBM’s immune evasion tactics.

The research team employed cutting-edge single-cell and spatial transcriptomic sequencing technologies on patient-derived GBM samples alongside robust animal models, revealing the existence of a distinct population of astrocytes within tumor microenvironments. Remarkably, this subset exhibits a potent ability to suppress the activity of tumor-targeting T cells, which are crucial foot soldiers in the body’s anti-cancer immune armamentarium. By effectively “disarming” these T cells, the specialized astrocytes create a sanctuary that allows glioblastoma cells to thrive unabated.

To dissect the functional relevance of this finding, the scientists utilized sophisticated in vivo genetic techniques to selectively disable these immunosuppressive astrocytes in mouse models of GBM. The results were striking—removal of this astrocyte subset reinvigorated T cell-mediated tumor attack, reshaped the tumor microenvironment into a more hostile territory, and significantly prolonged survival in these animals. These effects underscore not only the pivotal role these astrocytes play in glioblastoma progression but also their potential as novel therapeutic targets.

Moreover, the study identified that glioblastoma tumors actively co-opt this astrocyte-mediated suppression by releasing an inflammatory cytokine known as interleukin-11 (IL-11). This molecule functions as a potent activator of the T-cell killing capability within the astrocytes, thereby accelerating immune evasion and contributing to more rapid tumor growth and recurrence. Understanding this biochemical dialogue offers illuminating insights into the tumor’s insidious strategies of hijacking normal brain immune functions for its own survival advantage.

Harnessing this knowledge, the research team engineered an innovative therapeutic approach using oncolytic viruses—viruses designed to selectively infect and kill cancer cells—that were modified to produce an antibody targeting the IL-11 mediated pathway directly within the tumor’s microenvironment. This localized delivery system enabled the neutralization of the immunosuppressive signals in situ, allowing the immune system to mount a more robust and sustained attack against the tumor.

The implications of this work extend far beyond glioblastoma itself. By highlighting the central role astrocytes play in shaping immune responses within the brain, it opens avenues to potentially manipulate these cells in other neurological conditions where neuroinflammation and immune dysfunction are central pathological features. In the context of GBM, targeting the IL-11 activated astrocytes could finally pave the way towards effective immunotherapies that have thus far been elusive.

Given the notoriously immunosuppressive nature of the glioblastoma microenvironment, this discovery could represent a paradigm shift. Immunotherapy has revolutionized the treatment landscape of numerous cancers by empowering the patient’s own immune system, yet its failure in GBM has been a sobering reminder of the unique challenges posed by the central nervous system’s intricacies. By pinpointing the precise cellular and molecular actors responsible for this suppression, the study provides a critical foundation for the design of next-generation treatments.

Future research efforts will focus on expanding our understanding of how IL-11 influences not only astrocytes but also other cell populations residing within the tumor microenvironment. As glioblastoma cells and their surrounding stromal components maintain a dynamic and complex network of interactions, unraveling these relationships will be key to fully overcoming tumor immune escape. Additionally, investigating whether similar astrocyte-driven immunosuppressive mechanisms operate in brain metastases originating from other cancer types remains an intriguing and important question.

This study exemplifies the power of integrating advanced genomic and imaging techniques with innovative therapeutic design, showing how deep biological insights can be translated into practical interventions. Notably, the approach of delivering engineered antibodies via oncolytic viruses represents a highly versatile platform that could potentially be adapted to other molecular targets implicated in cancer or neurological diseases.

Ultimately, this transformative work not only provides hope for patients battling glioblastoma but also underscores the necessity of looking beyond cancer cells themselves to understand the broader cellular ecosystem that supports tumor survival. The identification of astrocytes as key modulators of anti-tumor immunity challenges prevailing notions and sets a new direction for brain tumor immunotherapy research.

As the scientific community continues to unravel the complex interplay between tumors and the immune system within the brain, this study stands out as a beacon illuminating a path toward therapies that could convert the brain’s own glial network from a shield for the tumor into an active participant in its eradication. With glioblastoma’s grim prognosis long unaltered, innovations such as this bring a timely and desperately needed breakthrough.

—

Subject of Research: Animals
Article Title: Glioblastoma-instructed astrocytes suppress tumor-specific T-cell immunity
News Publication Date: 21-May-2025
Web References: https://doi.org/10.1038/s41586-025-08997-x
References: Faust Akl C et al. “Glioblastoma-instructed astrocytes suppress tumor-specific T-cell immunity.” Nature. DOI:10.1038/s41586-025-08997-x
Image Credits: Not provided

The metabolic landscape of glioblastoma has remained notoriously difficult to decipher due to its complex cellular microenvironment and heterogeneous composition. Traditional bulk assays and imaging methods often blur the nuanced differences between individual tumor cells and their surrounding stroma. This study’s innovation lies in harnessing high-resolution MSI to spatially resolve metabolic activity at the cellular level. By integrating ^13C-labelled glucose, a canonical metabolic substrate, the team dynamically traced metabolic fluxes, revealing how distinct tumor cell populations exploit glucose metabolism differently, challenging the one-size-fits-all view of tumor energetics.

Glioblastoma’s metabolic reprogramming—specifically its altered glucose metabolism—has long been recognized, forming the foundation of diagnostic fluorodeoxyglucose PET imaging. However, the heterogeneity in glucose metabolic pathways across cellular subtypes within tumors had remained an enigma. Leveraging MSI of ^13C-glucose metabolism, the investigators could monitor multiple mass isotopologues corresponding to different metabolic intermediates, enabling fine-grained differentiation of glycolytic activity and downstream oxidative pathways. This dual approach marries spatial and metabolic specificity, unraveling the coexistence of divergent metabolic programs within the same tumor mass.

The results are striking: individual glioblastoma tumor cells display varying degrees of glycolytic flux versus oxidative phosphorylation, highlighting metabolic phenotypes that are intrinsic to each cell rather than solely influenced by microenvironmental cues. These intrinsic phenotypes suggest that tumor heterogeneity extends beyond genetic and epigenetic factors into the realm of metabolism, proposing a new axis of tumor classification. Such insights bear profound implications for metabolic inhibitors currently in development; therapies tailored by metabolic phenotype rather than histology could attain greater efficacy.

Furthermore, the research reveals that some tumor cells preferentially channel glucose-derived carbons into anabolic pathways supporting biosynthesis and rapid proliferation, whereas others maintain mitochondrial respiration to sustain survival under metabolic stress. This duality challenges the Warburg-centric paradigm that glycolysis dominates cancer metabolism and posits a more nuanced metabolic flexibility exploited by glioblastoma cells. Mapping this flexibility offers therapeutic windows to disrupt tumor survival strategies by inhibiting metabolic switches underpinning cellular adaptation.

The integration of mass spectrometry imaging with isotopic tracing represents a technical tour de force. Here, MSI operates not only as a molecular imaging tool but also as a quantitative analytical platform capable of distinguishing subtle isotope incorporations in metabolite pools with micrometer spatial resolution. This allows precise correlation of metabolic phenotypes with histopathological features such as necrosis, vascularization, and immune infiltration. As such, it blurs the traditional boundary between molecular biology and histopathology, creating a multidimensional framework to understand tumor biology.

From a clinical perspective, the potential to identify metabolic phenotypes in situ suggests new avenues for diagnostic imaging and biopsy analysis. For instance, metabolic phenotype signatures could serve as biomarkers to stratify patients whose tumors are more likely to respond to metabolic inhibitors. Moreover, real-time mapping of metabolic flux could inform surgical strategies by demarcating aggressive tumor regions metabolically distinct from adjacent, less aggressive tissue, guiding precision resections to maximize tumor removal while sparing normal brain.

The study also illuminates the adaptive metabolic reprogramming occurring in glioblastoma cells in response to therapeutic pressures. Tracking ^13C-glucose fate over time during treatment demonstrated cells dynamically altering their metabolic pathways, underpinning therapeutic resistance. This finding spotlights the importance of temporally resolved metabolic imaging to anticipate and counteract resistance mechanisms. It also underscores how future metabolic interventions must account for tumor plasticity to avoid transient responses.

Importantly, these findings extend beyond glioblastoma. The methodology can be applied to other cancers with metabolic heterogeneity, such as pancreatic, lung, or breast carcinomas, where intratumoral variability fuels therapeutic failure. By adopting MSI of isotopically labelled metabolites, oncologists and researchers may soon routinely uncover the metabolic fingerprints unique to individual tumors, heralding an era of metabolism-driven oncology precision.

The collaborative nature of this work, integrating mass spectrometry experts, neuro-oncologists, biochemists, and computational scientists, exemplifies the interdisciplinary approach essential to solve complex biological puzzles. Sophisticated data analysis pipelines were crucial to interpret the voluminous MSI data, transforming raw spectral information into meaningful metabolic maps. Machine learning algorithms facilitated the identification of metabolic phenotypes, enabling unsupervised clustering that unveiled previously unrecognized metabolic subpopulations within tumors.

Underlying this research is the quest to resolve long-standing questions about metabolic dependencies in cancer. While genomic and transcriptomic analyses have revolutionized oncology, they offer indirect insights into metabolism. Here, direct measurement of metabolite fluxes provides concrete evidence linking metabolic states to cellular function and disease behavior. Such data are indispensable for rational drug design targeting metabolic enzymes or transporters essential for tumor growth.

The study also underscores the importance of isotope labelling strategies. By using ^13C-labelled glucose, the investigators traced how glucose carbons are incorporated into diverse metabolic pathways—including glycolysis, the tricarboxylic acid cycle, and biosynthetic routes—highlighting the routes exploited by tumor cells. This dynamic perspective contrasts with static metabolite measurements and captures the real-time metabolic flux, essential to understand tumor metabolism’s adaptive landscapes fully.

Looking forward, integration of MSI metabolic imaging with other omics approaches, such as single-cell transcriptomics and proteomics, could yield holistic multi-layered portraits of tumor biology. This integration could decipher how metabolic phenotypes relate to gene expression signatures and protein activities, fostering a systems biology understanding of tumor heterogeneity. Such comprehensive approaches will be vital to identify robust metabolic vulnerabilities for therapeutic exploitation.

Moreover, this metabolic profiling technology may influence the development of novel metabolic imaging agents for non-invasive diagnostics. Imaging modalities that can detect distinctive metabolic signatures in vivo would revolutionize tumor detection and monitoring. Coupled with personalized medicine paradigms, these imaging tools could facilitate early diagnosis, monitor therapeutic response, and detect relapse with unprecedented specificity.

In essence, the discovery of cell-intrinsic metabolic phenotypes within glioblastoma represents a paradigm shift, propelling metabolism to the forefront of cancer biology. It challenges existing dogmas, expands conceptual frameworks, and injects fresh optimism into the quest for therapies against this devastating malignancy. As metabolic-targeted drugs advance through clinical trials, insights from studies like this will be seminal in guiding their precise application to maximally benefit patients.

The research enshrined in this work is a beacon for future studies, demonstrating that untangling metabolic complexity at the cellular level is not only feasible but critical. It charts a roadmap for translating cutting-edge mass spectrometry and isotope tracing methodologies into clinical practice, enabling a smarter war against cancer by targeting its metabolic Achilles’ heel.

Subject of Research:
Glioblastoma metabolic heterogeneity characterized by cell-intrinsic metabolic phenotypes, revealed through mass spectrometry imaging of ^13C-labelled glucose metabolism.

Article Title:
Cell-intrinsic metabolic phenotypes identified in patients with glioblastoma, using mass spectrometry imaging of ^13C-labelled glucose metabolism.

Article References:
Tsyben, A., Dannhorn, A., Hamm, G. et al. Cell-intrinsic metabolic phenotypes identified in patients with glioblastoma, using mass spectrometry imaging of ^13C-labelled glucose metabolism. Nat Metab (2025). https://doi.org/10.1038/s42255-025-01293-y

Image Credits:
AI Generated